Medication combines two bronchodilators, experts say.
(HealthDay)—A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration.
GlaxoSmithKline's Anoro Ellipta is meant to be used once a day for long-term maintenance of airflow in patients with COPD. The lung disease makes breathing difficult and worsens over time.
"Anoro Ellipta works by helping the muscles around the airways of the lungs stay relaxed to increase airflow in patients with COPD," Dr. Curtis Rosebraugh, director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research, said in an agency news release.
"The availability of new long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD," he added.
Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, said the new medication is a "unique combination" of two drugs presently used for COPD. "It combines a drug similar to Spiriva and a [long-acting beta agonist] as found in Advair, he said. "There is no steroid in Anoro Ellipta."
According to the FDA, Anoro Ellipta combines umeclidinium, a drug that prevents muscles around the large airways from tightening, and vilanterol, which improves breathing by relaxing the muscles of the airways to allow more air to flow into and out of the lungs.
Another lung specialist, Dr. Charles Powell, called the approval a "promising development for patients with COPD," noting other countries already allow this type of medication.
"Combined long-acting bronchodilators are available in Europe. Now we have the first approved combined long-acting bronchodilator medication available in the U.S.," said Powell, who is chief of pulmonary, critical care and sleep medicine at the Mount Sinai - National Jewish Health Respiratory Institute in New York City.
"Combining two effective bronchodilators can result in improved lung function and medication compliance compared to traditional COPD inhaled medications," Powell said.
The FDA approval is based on findings from more than 2,400 people with COPD. The results showed that those who took the drug had greater improvements in lung function than those who took a placebo. The most common side effects reported by patients who took Anoro Ellipta included sore throat, sinus infection, lower respiratory tract infection, constipation, diarrhea, pain in extremities, muscle spasms, neck pain and chest pain.
Serious side effects that can be caused by the drug include narrowing and obstruction of the airway, cardiovascular effects, increased pressure in the eyes, and worsening of urinary retention.
Anoro Ellipta is not approved for asthma treatment and should not be used as a rescue treatment for sudden breathing problems, the FDA said. The drug carries a boxed warning that the class of drugs that vilanterol belongs to increases the risk of asthma-related death.
"Patients with COPD need to be seen and examined before determining the appropriate use of this drug, as with any medication," added Horovitz.
Cigarette smoking is the main contributor to COPD, which is the third leading cause of death in the United States. Symptoms can include chest tightness, chronic cough and excessive phlegm.
Explore further: FDA approves once-a-day inhaler from Glaxo
More information: The U.S. National Library of Medicine has more about COPD.
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
FDA approves once-a-day inhaler from Glaxo
May 10, 2013
The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease.
Tudorza pressair approved for COPD
Jul 24, 2012
(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) ...
US panel backs inhaler drug for lung disease
Apr 17, 2013
A panel of U.S. respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease.
Opsumit approved for pulmonary arterial hypertension
Oct 23, 2013
(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.
New class of drug shows promise for treating asthma and COPD
Oct 24, 2013
Scientists have developed a new drug (RPL554) that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) in two ways at once, according to new research published in The Lancet Re ...
Recommended for you
CDC issues travel health advisory for St. Martin
40 minutes ago
U.S. health authorities have issued a travel advisory for the French Caribbean dependency of St. Martin because of a mosquito-borne viral disease that is apparently being spread locally at the start of the winter tourist ...
Researchers identify genetic marker of resistance to key malaria drug
2 hours ago
An international team of researchers has discovered a way to identify, at a molecular level, malaria-causing Plasmodium falciparum parasites that are resistant to artemisinin, the key drug for treating this disease. The research ...
Fight against malaria slows, fewer nets given out
6 hours ago
Global efforts to curb malaria are stalling after a drop in funds to buy bed nets, according to the latest report Wednesday from the World Health Organization.
Flusurvey: Preliminary findings released
7 hours ago
Preliminary results from the first month of the Flusurvey run by scientists at the London School of Hygiene & Tropical Medicine indicate that flu is yet to take hold of the UK, with just 6,000 cases per 100,000 people reported, ...
Dialysis is no laughing matter; however researchers are now asking if it should be
8 hours ago
For 11,000 Australians kidney dialysis is not something to laugh about. However a good chuckle might well be the best thing for them.
China says woman died from bird flu new to humans
13 hours ago
Chinese authorities said Wednesday that a 73-year-old Chinese woman died after being infected with a bird flu strain that had sickened a human for the first time, a development that the World Health Organization called "worrisome."
User comments
© Medical Xpress 2011-2013, Science X network
Medication combines two bronchodilators, experts say.
(HealthDay)—A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration.
GlaxoSmithKline's Anoro Ellipta is meant to be used once a day for long-term maintenance of airflow in patients with COPD. The lung disease makes breathing difficult and worsens over time.
"Anoro Ellipta works by helping the muscles around the airways of the lungs stay relaxed to increase airflow in patients with COPD," Dr. Curtis Rosebraugh, director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research, said in an agency news release.
"The availability of new long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD," he added.
Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, said the new medication is a "unique combination" of two drugs presently used for COPD. "It combines a drug similar to Spiriva and a [long-acting beta agonist] as found in Advair, he said. "There is no steroid in Anoro Ellipta."
According to the FDA, Anoro Ellipta combines umeclidinium, a drug that prevents muscles around the large airways from tightening, and vilanterol, which improves breathing by relaxing the muscles of the airways to allow more air to flow into and out of the lungs.
Another lung specialist, Dr. Charles Powell, called the approval a "promising development for patients with COPD," noting other countries already allow this type of medication.
"Combined long-acting bronchodilators are available in Europe. Now we have the first approved combined long-acting bronchodilator medication available in the U.S.," said Powell, who is chief of pulmonary, critical care and sleep medicine at the Mount Sinai - National Jewish Health Respiratory Institute in New York City.
"Combining two effective bronchodilators can result in improved lung function and medication compliance compared to traditional COPD inhaled medications," Powell said.
The FDA approval is based on findings from more than 2,400 people with COPD. The results showed that those who took the drug had greater improvements in lung function than those who took a placebo. The most common side effects reported by patients who took Anoro Ellipta included sore throat, sinus infection, lower respiratory tract infection, constipation, diarrhea, pain in extremities, muscle spasms, neck pain and chest pain.
Serious side effects that can be caused by the drug include narrowing and obstruction of the airway, cardiovascular effects, increased pressure in the eyes, and worsening of urinary retention.
Anoro Ellipta is not approved for asthma treatment and should not be used as a rescue treatment for sudden breathing problems, the FDA said. The drug carries a boxed warning that the class of drugs that vilanterol belongs to increases the risk of asthma-related death.
"Patients with COPD need to be seen and examined before determining the appropriate use of this drug, as with any medication," added Horovitz.
Cigarette smoking is the main contributor to COPD, which is the third leading cause of death in the United States. Symptoms can include chest tightness, chronic cough and excessive phlegm.
Explore further: FDA approves once-a-day inhaler from Glaxo
More information: The U.S. National Library of Medicine has more about COPD.
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
FDA approves once-a-day inhaler from Glaxo
May 10, 2013
The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease.
Tudorza pressair approved for COPD
Jul 24, 2012
(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) ...
US panel backs inhaler drug for lung disease
Apr 17, 2013
A panel of U.S. respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease.
Opsumit approved for pulmonary arterial hypertension
Oct 23, 2013
(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.
New class of drug shows promise for treating asthma and COPD
Oct 24, 2013
Scientists have developed a new drug (RPL554) that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) in two ways at once, according to new research published in The Lancet Re ...
Recommended for you
CDC issues travel health advisory for St. Martin
40 minutes ago
U.S. health authorities have issued a travel advisory for the French Caribbean dependency of St. Martin because of a mosquito-borne viral disease that is apparently being spread locally at the start of the winter tourist ...
Researchers identify genetic marker of resistance to key malaria drug
2 hours ago
An international team of researchers has discovered a way to identify, at a molecular level, malaria-causing Plasmodium falciparum parasites that are resistant to artemisinin, the key drug for treating this disease. The research ...
Fight against malaria slows, fewer nets given out
6 hours ago
Global efforts to curb malaria are stalling after a drop in funds to buy bed nets, according to the latest report Wednesday from the World Health Organization.
Flusurvey: Preliminary findings released
7 hours ago
Preliminary results from the first month of the Flusurvey run by scientists at the London School of Hygiene & Tropical Medicine indicate that flu is yet to take hold of the UK, with just 6,000 cases per 100,000 people reported, ...
Dialysis is no laughing matter; however researchers are now asking if it should be
8 hours ago
For 11,000 Australians kidney dialysis is not something to laugh about. However a good chuckle might well be the best thing for them.
China says woman died from bird flu new to humans
13 hours ago
Chinese authorities said Wednesday that a 73-year-old Chinese woman died after being infected with a bird flu strain that had sickened a human for the first time, a development that the World Health Organization called "worrisome."
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment